Premium
Efficacy and safety of once‐daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk
Author(s) -
Meltzer Eli O.,
Lee Jane,
Tripathy Ita,
Lim Junghee,
Ellsworth Anna,
Philpot Edward
Publication year - 2009
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/j.1399-3038.2008.00773.x
Subject(s) - medicine , fluticasone propionate , nasal spray , placebo , nasal administration , population , fluticasone , allergy , corticosteroid , nose , anesthesia , surgery , pharmacology , immunology , alternative medicine , environmental health , pathology
The objective of this study was to evaluate the efficacy and safety of fluticasone furoate (FF) nasal spray 55 and 110 μg once daily in children with seasonal allergic rhinitis (SAR). Patients (n = 554) received placebo nasal spray or FF, administered using a unique side‐actuated device, in a 2‐wk, randomized, double‐blind study. Symptoms were evaluated by patients using a 4‐point categorical scale. Efficacy assessments included reflective and instantaneous total nasal symptom scores (r/iTNSS). Primary analyses were conducted in patients aged 6–11 yr in the intent‐to‐treat population (ITT); the 2–11 yr group provided supportive analyses. In patients aged 6–11 yr, FF 110 μg once daily significantly improved the daily rTNSS compared with placebo. FF 55 μg once daily was only numerically better for rTNSS and iTNSS. Secondary pre‐dose iTNSS and overall response to therapy were significant with FF 110 μg. The significant findings for FF 110 μg were supported by analyses in the entire ITT population of 2–11 yr olds. Both doses of FF were well tolerated. These study results suggest that FF nasal spray administered once daily for 2 wk is well tolerated and effective for the treatment of SAR symptoms in children aged 2–11 yr.